The policy stagnation of recent years, where change has been almost entirely focused on pricing, belies a history of significant structural shifts to ensure the program can better accommodate patient needs. …
The system can innovate for patients, when it wants, but history shows it rarely involves HTA
May 31, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News